조직 진단약 시장 : 제품, 기술, 적응증, 최종사용자별 - 세계 예측(2025-2030년)

The Tissue Diagnostics Market was valued at USD 8.30 billion in 2023, expected to reach USD 8.94 billion in 2024, and is projected to grow at a CAGR of 7.76%, to USD 14.02 billion by 2030.

The tissue diagnostics market encompasses tools and technologies used to analyze and detect diseases at the cellular level, primarily in the realm of cancer diagnostics but extending to other areas such as infectious diseases and histopathological studies. The necessity of tissue diagnostics is underscored by its critical role in precision medicine, enabling tailored treatment regimens based on individual patient pathology. Applications include but are not limited to, immunohistochemistry, in situ hybridization, digital pathology, and special staining, which find significant end-use in hospitals, research laboratories, and diagnostic clinics. Growth in the tissue diagnostics market is driven by factors such as the increasing prevalence of cancer, advances in biomarker research, and technological innovations in diagnostic techniques. A notable opportunity lies in the integration of digital pathology and AI-driven analytics to enhance diagnostic accuracy and workflow efficiency. This could help address challenges like skill shortages and the increasing demand for rapid diagnostics. Limitations, however, consist of the high costs of advanced diagnostic tools and infrastructure, regulatory barriers, and a lack of skilled personnel in some regions, slowing adoption rates. Additionally, the inherent complexity of tissue sample preservation and analysis can pose operational challenges. Innovation and research areas with significant potential include the development of portable, cost-effective diagnostic kits for point-of-care testing and the further refinement of AI algorithms for predictive analytics in pathology. The market is characterized by a competitive landscape with ongoing collaborations and mergers among prominent players aiming to expand their product portfolios and geographical reach. Consumer demand for personalized medical solutions and the increasing investment in healthcare infrastructure, particularly in emerging economies, are expected to provide substantial market opportunities. Companies should focus on strategic partnerships with technology firms and research institutions to harness innovative solutions that address existing limitations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tissue Diagnostics Market

The Tissue Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of cancer worldwide
  • Growing use of personalized medicine
  • Government initiatives to increase awareness regarding effective and early cancer diagnosis
• Market Restraints
  • High cost involved in tissue diagnosis and reimbursement issues
• Market Opportunities
  • Inception of digital pathology and automated tissue diagnostics
  • Innovative technologies and instruments development in tissue diagnostic field
• Market Challenges
  • Limitations associated with tissue diagnostics procedures coupled with privacy concerns

Porter's Five Forces: A Strategic Tool for Navigating the Tissue Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tissue Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tissue Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tissue Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tissue Diagnostics Market

A detailed market share analysis in the Tissue Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tissue Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tissue Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Tissue Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam Plc, Agilent Technologies, Inc., Atlas Antibodies AB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biogenex Laboratories Inc., BioIVT, LLC, bioMerieux SA, Cardinal Health, Inc., Castle Biosciences, Inc., Cell Signaling Technology, Inc., Diagnostic BioSystems Inc., F. Hoffmann-La Roche Ltd, Leica Biosystems by Danaher Corporation, McKesson Corporation, Merck KGaA, MILESTONE MEDICAL Srl, PathAI, Inc., Pfizer Inc., PROGEN Biotechnik GmbH, QIAGEN N.V., Quest Diagnostics Incorporated, Sekisui Diagnostics, LLC, Siemens Healthineers AG, SLEE medical GmbH, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Tissue Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Accessories, Consumables, Instruments, and Software. The Consumables is further studied across Antibodies, Kits, Probes, and Reagents. The Instruments is further studied across Scanners, Slide-staining Systems, Tissue Microarrays, and Tissue-processing Systems.
• Based on Technology, market is studied across Digital Pathology & Workflow, Immunohistochemistry, In Situ Hybridization, and Special Staining.
• Based on Indications, market is studied across Breast Cancer, Gastric Cancer, Lymphoma, Non Small Cell Lung Cancer, and Prostate Cancer.
• Based on End-User, market is studied across Clinical Pathology, Contract Research Organization, Hospitals, Pharmaceutical Organizations, and Research Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of cancer worldwide
    • 5.1.1.2. Growing use of personalized medicine
    • 5.1.1.3. Government initiatives to increase awareness regarding effective and early cancer diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost involved in tissue diagnosis and reimbursement issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Inception of digital pathology and automated tissue diagnostics
    • 5.1.3.2. Innovative technologies and instruments development in tissue diagnostic field
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations associated with tissue diagnostics procedures coupled with privacy concerns
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Proliferating use of tissue-processing systems for efficient processing and analyzing diagnosing tissue samples
  • 5.2.2. Technology: Adoption of digital pathology technology for the management of digitized histological samples through computer technology
  • 5.2.3. Indications: Exponential use of tissue diagnostics in the detection and characterization of numerous cancer types
  • 5.2.4. End-User: Significant utilization of tissue diagnostics in clinical pathology laboratories to improve patient care quality
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Tissue Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Accessories
• 6.3. Consumables
  • 6.3.1. Antibodies
  • 6.3.2. Kits
  • 6.3.3. Probes
  • 6.3.4. Reagents
• 6.4. Instruments
  • 6.4.1. Scanners
  • 6.4.2. Slide-staining Systems
  • 6.4.3. Tissue Microarrays
  • 6.4.4. Tissue-processing Systems
• 6.5. Software

7. Tissue Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Digital Pathology & Workflow
• 7.3. Immunohistochemistry
• 7.4. In Situ Hybridization
• 7.5. Special Staining

8. Tissue Diagnostics Market, by Indications

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Gastric Cancer
• 8.4. Lymphoma
• 8.5. Non Small Cell Lung Cancer
• 8.6. Prostate Cancer

9. Tissue Diagnostics Market, by End-User

• 9.1. Introduction
• 9.2. Clinical Pathology
• 9.3. Contract Research Organization
• 9.4. Hospitals
• 9.5. Pharmaceutical Organizations
• 9.6. Research Laboratories

10. Americas Tissue Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Tissue Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Tissue Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services
  • 13.3.2. Ibex Raises USD 55 Million in Series C Funding to Drive Global Adoption of AI for Cancer Diagnosis
  • 13.3.3. Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading
  • 13.3.4. Cytelabs expanding diagnostic services to hospitals and patients across south India
  • 13.3.5. Bio-Techne Buys Lunaphore to Boost Cancer Diagnostics Through Spatial Biology
  • 13.3.6. Lunaphore Secures Chf 40 Million to Boost Portfolio of Tissue Diagnostics Solutions
  • 13.3.7. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
  • 13.3.8. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
  • 13.3.9. Roche Expands Collaboration with Janssen to Advance Personalized Healthcare Through Companion Diagnostics
  • 13.3.10. Guardant Health to Integrate Lunit's Ai-Based Scoring Algorithm for Pd-L1 into its Portfolio to Enhance Cancer Biomarker Detection
  • 13.3.11. Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine Partnership Will Pave the Way for New RegenMed Clinical Trials Catalyst Program
  • 13.3.12. Microsoft Strikes Partnership with Paige to Advance Cancer Diagnostics and Treatment
  • 13.3.13. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
  • 13.3.14. Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
  • 13.3.15. ROCHE tissue diagnostics celebrates marana expansion project

Companies Mentioned

• 1. Abbott Laboratories
• 2. Abcam Plc
• 3. Agilent Technologies, Inc.
• 4. Atlas Antibodies AB
• 5. Bio-Rad Laboratories, Inc.
• 6. Bio-Techne Corporation
• 7. Biogenex Laboratories Inc.
• 8. BioIVT, LLC
• 9. bioMerieux SA
• 10. Cardinal Health, Inc.
• 11. Castle Biosciences, Inc.
• 12. Cell Signaling Technology, Inc.
• 13. Diagnostic BioSystems Inc.
• 14. F. Hoffmann-La Roche Ltd
• 15. Leica Biosystems by Danaher Corporation
• 16. McKesson Corporation
• 17. Merck KGaA
• 18. MILESTONE MEDICAL Srl
• 19. PathAI, Inc.
• 20. Pfizer Inc.
• 21. PROGEN Biotechnik GmbH
• 22. QIAGEN N.V.
• 23. Quest Diagnostics Incorporated
• 24. Sekisui Diagnostics, LLC
• 25. Siemens Healthineers AG
• 26. SLEE medical GmbH
• 27. Thermo Fisher Scientific Inc.